InspireMD Announces the Distribution of CGuard™ Embolic Prevention System in South Africa
January 14, 2019 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Jan. 14, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Receives Noncompliance Notice from NYSE American
January 11, 2019 16:30 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Publication of Meta-Analysis Citing Benefits of Next Generation Mesh-Covered Carotid Stent Systems
December 18, 2018 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Dec. 18, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)
November 29, 2018 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Regulatory and Reimbursement Approval of CGuard™ Embolic Prevention System in Australia
November 28, 2018 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Nov. 28, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Upcoming Presentations at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)
November 13, 2018 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Third Quarter 2018 Financial Results and Provides Corporate Update
November 06, 2018 07:00 ET
|
InspireMD, Inc.
Presented Three-Year Data Highlighting Long-Term Safety and Efficacy of CGuard™ Embolic Prevention System On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am...
InspireMD to Report Third Quarter 2018 Financial Results and Provide Business Update on Tuesday, November 6
October 30, 2018 08:00 ET
|
InspireMD, Inc.
Conference Call Scheduled for 8am Eastern Time TEL AVIV, Israel, Oct. 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS)...
InspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference
September 27, 2018 09:28 ET
|
InspireMD, Inc.
Preliminary Three-Year Data Continue to Show Unprecedented Safety, Efficacy and Durability of Stroke Prevention in Treating Carotid Artery Stenosis TEL AVIV, Israel, Sept. 27, 2018 (GLOBE NEWSWIRE)...
InspireMD Announces Regulatory Approval of CGuard™ Embolic Prevention System in Mexico
September 24, 2018 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Sept. 24, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...